FindTrial
Sign In

Identifying Characteristic Signature of Attention Deficit / Hyperactivity Disorder (ADHD) and Ritalin Treatment

Identifying Characteristic Signature of Brain Activity of Electroencephalogram Records in Attention Deficit / Hyperactivity Disorder (ADHD) and Ritalin Treatment

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01962181
Enrollment
40
Registered
2013-10-14
Start date
2013-10-31
Completion date
2015-12-31
Last updated
2013-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Attention Deficit Hyperactivity Disorder

Keywords

EEG Attention Deficit / Hyperactivity Disorder (ADHD) Ritalin machine learning

Brief summary

In this study we try to identify the signature of brain activity in the EEG of attention deficit disorder (ADHD) patients compared to healthy subjects under different doses of Ritalin (methylphenidate) treatment.

Detailed description

In this study we try to identify the signature of brain activity in the EEG of attention deficit disorder (ADHD) patients compared to healthy subjects under different doses of Ritalin (methylphenidate) treatment. All subjects will undergo 1-4 EEG sessions. In each session we will use a different dose of Ritalin or placebo. A detailed neuropsychological tests will be done during the EEG recording. A powerful machine-learning techniques will be used in order to find a specific signature of ADHD and Ritalin treatment in the EEG recording.

Interventions

DRUGRitalin

Patients with ADHD and healthy subjects will be examined under Ritalin or placebo

DRUGPlacebo

Sponsors

Hadassah Medical Organization
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes

Inclusion criteria

* Healthy subjects, aged 18-50 years. * Subjects aged 18-50 years diagnosed with ADHD and treated with Ritalin regularly (at least once a week).

Exclusion criteria

* Patients previously diagnosed as suffering from a brain disease except for ADHD. * Patients after traumatic head injury. * Patients who are unable to express their consent to participate in the study.

Design outcomes

Primary

MeasureTime frameDescription
Resting oscillation activity and Event-related-Potentials in Attention Deficit / Hyperactivity Disorder (ADHD) and healthy subjects.2 yearsThe primary outcome measure is the difference in the analysis of EEG recording (for example, resting oscillation activity and Event-related-Potentials) in Attention Deficit / Hyperactivity Disorder (ADHD) vs. healthy subjects.

Countries

Israel

Contacts

Primary ContactRenana Eitan, MD
renanaeitan@gmail.com
Backup ContactShahar Arzy, MD

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026